Asia Pacific Orthopedic Biometrial Market Size was valued at USD 22.67 Billion in 2023. The Asia Pacific Orthopedic Biometrial industry is projected to grow from USD 23.88 Billion in 2024 to USD 42.23 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.64% during the forecast period (2024 - 2032). Orthopedic biomaterials are organic or synthetic materials used for the treatment of internal fractures. During the last decade different new techniques and materials are introduced for orthopedic implants and surgeries and biomaterials have found a vital role in it.Â
These biomaterials are used in manufacturing of different implants since they do not evoke any immunological reactions with the body, which makes it a first choice for manufacturing of implants. Increasing demand for the orthopedic biomaterial because of its application in knee and hip replacement surgeries, and increasing incident of medical emergencies drive the Asia Pacific orthopedic biomaterial market.
Introduction of novel implants of titanium has increased the success rate of implant surgeries and also contributed to the growth of the orthopedic market in Asia Pacific. Moreover, increasing number of orthopedic surgeries, increasing aging population, and growing governmental support also drive the Asia Pacific market. However, increasing failure in joints implants, stringent regulatory laws, and high cost of treatment may hinder the growth of Asia Pacific orthopedic biomaterial market during the review period.
Orthopedic biomaterials might be artificial or natural. They are made to be inserted into a person's body as parts of machines that are intended to carry out certain biological tasks by replacing or mending various tissues. Orthopedic biomaterials are utilized for tissue fixation, spine implants, joint replacements, and other orthopedic procedures. Additionally, the need for next-generation orthopedic biomaterials specifically designed to fulfill the requirements of a particular orthopedic operation is on the rise globally. On the other hand, the market's expansion has been hampered by the restricted payment coverage alternatives for these devices and the falling reimbursement for orthopedic implants in several nations. Additionally, the lack of rebates has forced suppliers to reduce the cost of these products, which has slowed market expansion.
The growing geriatric population, rising incidence rates of accidents and sports-related injuries, rising awareness of orthopedic biomaterials, and introduction of novel products by major market players are a few of the factors anticipated to boost market growth over the forecast period. Fewer traffic accidents and injuries occurred due to the pandemic's widespread lockdowns, curtailing private and public transit. As a result, the focus of healthcare institutions shifted from operations to COVID-19 patients. This immediately affected the market during the early pandemic phase, especially in specialist hospitals. Increased bone fractures, disc degenerative disorders, and more trauma cases are predicted to increase product demand in this market. Due to factors like the rising geriatric population, increasing incidence rates of accidents and sports-related injuries, and rising awareness of orthopedic biomaterials.
CitrefixTM, a suture anchor system for surgical procedures on the foot and ankle, was introduced by Stryker. The new technology uses CitregenTM, a highly acclaimed bioresorbable substance created to imitate the composition and structure of natural bone. Citrefix is a resorbable, bio-inspired suture anchor system for single-use sutures. Citregen, an elastomeric substance formed from a citrate polymer and specifically created to imitate bone chemistry for regulated resorption without persistent inflammation, is used in its construction. These special chemical and mechanical qualities are intended to promote healthy bone growth and heal transplanted tissue when used in orthopedic surgical procedures.
Some of the major players in Asia Pacific orthopedic biomaterial market:Â
The orthopedic biomaterials market is segmented on the basis of types of material, applications, and end users. On the basis of types of material, the market is segmented into metals and non-metals. The metals are further segmented into stainless steel, titanium alloy, cobalt alloy, and others. Non-metal are further segmented into ceramic, polymeric, natural biomaterials, and others. The ceramic are sub-segmented into alumina, calcium phosphate, zirconium dioxide, carbon, and others. The polymeric materials are sub-segmented into polymethylmethacrylate (PMMA), polyethylene, silicone, polyester, and other. The natural biomaterials are sub-segmented into collagen, chitin & chitosan, and other
On the basis of applications, the Asia Pacific orthopedic biomaterial market is segmented into joint replacement, fracture fixation devices, tissue fixation, spine implants, viscosupplementation, and other. Joint replacement is sub-segmented into hip replacement, knee replacement, shoulder and elbow replacement, and other. Tissue fixation is sub-segmented into interference screws, suture anchors, and others. Spine implants are further sub-segmented into spine fusion and other. The fracture fixation devices are sub segmented into screws, plates for bones, rods, and other.
On the basis of end users, the Asia Pacific orthopedic biomaterial market is segmented into hospital, clinics, and others.The first surgical application of Acuitive Technologies, Inc.'s (Acuitive) Citrelock® ACL Tendon Fixation Device was disclosed. The novel ACL device offers orthopedic surgeons a unique design thanks to a tendon-friendly spiral thread made of Citregen, a next-generation resorbable material with special molecular and mechanical characteristics. With its cutting-edge material technology and distinctive design, the Citrelock ACL Tendon Fixation Device contributes to meeting this therapeutic requirement. The Citrelock ACL System is an exciting new addition to Acuitive's line of products and the first of many that we will be releasing with an emphasis on the sports medicine sector.
China dominates the Asia Pacific orthopedic biomaterial market owing to increasing prevalence of different orthopedic surgeries in China. Increasing awareness of biodegradable products among the people, rapid research and development and huge aging population in this region have added fuel to the growth of the market. Japan and Australia are other major contributor of the Asia Pacific orthopedic biomaterial market in this region.Â
Intended Audience
| Attribute/Metric | Details |
| Market Size 2023 | 22.67 (USD Billion) |
| Market Size 2024 | 23.88 (USD Billion) |
| Market Size 2032 | 42.23 (USD Billion) |
| Compound Annual Growth Rate (CAGR) | 10.64 % (2024 - 2032) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year | 2023 |
| Market Forecast Period | 2024 - 2032 |
| Historical Data | 2019 - 2023 |
| Â Â Geographies Covered | Â Â North America, Europe, Asia Pacific |
| Â Â Key Vendors | Â Â Stryker (US) CoorsTek Inc. (US) Zimmer Biomet Holdings Inc. (US) Institut Straumann AG (Switzerland) Kyocera Corporation (Japan) Smith & Nephew plc (UK) 3M (US) Nobel Biocare Services AG(Switzerland) Medtronicplc (Ireland) DePuy Synthes (US) |
| Â Â Key Market Opportunities | Â Â Technological advancement in the medical implants market |
| Â Â Key Market Drivers | Â Â Increasing older population leading to an increase in the patient population |
Asia Pacific Orthopedic Biometrial Market Highlights:
Frequently Asked Questions (FAQ) :
The Asia Pacific Orthopedic Biomaterial Market CAGR would be 10.64% during the forecast period (2024-2032).
End users in the Asia Pacific Orthopedic Biomaterial Market are hospitals, clinics, and others.
China would dominate the Asia Pacific Orthopedic Biomaterial Market.
The applications of the Asia Pacific Orthopedic Biomaterial Market are viscosupplementation, fracture fixation devices, joint replacement, spine implants, tissue fixation, and other
Players involved are Materion Corporation (US), Kyocera Corporation (Japan), InVision Biomedical (US), S&V Technologies (Germany), Rayner (UK), Invibio Ltd. (U.K.), Royal DSM (Netherlands), Covestro (Germany), Corbion N.V. (Netherlands), BASF SE (Germany), Tianjin Walkman Biomaterial Co. (China), CeramTec (Germany), Cam Bioceramics B.V. (Netherland), Johnson & Johnson Services, Inc. (US), Kanghui Holdings (China), and Xian Airfoil Technology Co (China).
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
